• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: May 2023

Editor's Choice

Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks

May 25, 2023 Luis Gosálbez

Abstract Microbiome drug development has captured significant interest over the last decade. However, despite the recent clinical and regulatory success stories, this area is lately regarded as a high-risk one by investors given the current […]

Pharma & Human Health

Vaginal probiotics quietly making progress in drug reclassification in the EU

May 23, 2023 Luis Gosálbez

Original Source: Sandwalk Bioventures The Spanish Medicines Agency (AEMPS) just authorized its first-ever drug based on live microorganisms for vaginal application. Muvagyn®, containing live L. gasseri and L. rhamnosus, is indicated for the normalisation of […]

Finance

BiomeSense Closes Oversubscribed $3 Million Funding Round

May 22, 2023 Microbiome Times

BiomeSense, a biotech company unlocking the vast health benefits of the microbiome through novel “smart bathroom” hardware technology and advanced bioinformatics, announced the close of its oversubscribed $3 million funding round. Led by Bluestein Ventures, the financing […]

Pharma & Human Health

NIH launches largest precision nutrition research effort of its kind

May 19, 2023 Microbiome Times

The National Institutes of Health is now enrolling participants in a landmark initiative to advance nutrition research. Nutrition for Precision Health, powered by the All of Us Research Program, or NPH, is working with 14 […]

Pharma & Human Health

Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds

May 17, 2023 Microbiome Times

Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety. The positive influence of Cerebiome® on the gut microbiota […]

Pharma & Human Health

Exhaled breath can reveal crucial insight into the microbiome

May 12, 2023 Madeleine Ball

The microbiome challenges what it means to be an individual. Our understanding of the factors that contribute to health and disease has been revolutionized by the discovery that the human body is colonized by an […]

Editor's Choice

DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device

May 10, 2023 Sanna Abbasi, Ph.D.

Historically, researchers have surveyed the composition and/or expression of microorganisms within the human gut microbiome by collecting fecal samples, isolating microbial nucleic acids, and using those nucleic acids to analyze the microbial species present within […]

Finance

Solarea Bio Announces First Close of Series B Financing Round

May 9, 2023 Microbiome Times

Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of […]

Finance

SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

May 8, 2023 Microbiome Times

SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces that Nature Biotechnology has published research findings from its preclinical work on SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and […]

Uncategorized

New discovery stops bacterial virus contamination

May 3, 2023 Microbiome Times

A new discovery by researchers at the University of Warwick could help stop bacteria being contaminated with viruses, reducing disruption and decreasing costs in industry and research. Bacteria are routinely used in biological and biomedical […]

Finance

Recipharm will manufacture VOWST on behalf of Seres Therapeutics

May 2, 2023 Microbiome Times

Recipharm, a global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) as a manufacturing site of VOWST, a […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
sign up

Sign up to the Microbiome Times newsletter